Abstract
Somatic mutations in the promoter region of telomerase reverse transcriptase (TERT), a critical mechanism for telomerase reactivation, play a key role in tumorigenesis. The status of TERT promoter mutation serves as a crucial molecular biomarker for glioma assessment and classification, and is essential for early diagnosis of glioma subtypes, guiding treatment decision-making, and improving patient prognosis. With the recognition of the importance of molecular subtyping of gliomas, there has been a surge in research on non-invasive prediction of key molecular biomarkers based on preoperative imaging of gliomas, with a particular focus on TERT promoter studies using radiomics approaches. This article presents a comprehensive review of research on TERT promoter mutations in gliomas and imaging-related studies, with the goal of providing insights for future studies on non-invasive prediction of TERT promoters status and offering important references for the precision diagnosis and treatment of glioma patients.